Misplaced Pages

Umeclidinium bromide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Umeclidinium) Chemical compound Pharmaceutical compound
Umeclidinium bromide
Clinical data
Trade namesIncruse Ellipta
Other namesGSK573719A
License data
Routes of
administration
Inhalation (DPI)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding~89%
MetabolismLiver (CYP2D6)
Elimination half-life11 hours
ExcretionFeces (58%) and urine (22%)
Identifiers
IUPAC name
  • Diphenyl-octan-4-yl]methanol bromide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.166.375 Edit this at Wikidata
Chemical and physical data
FormulaC29H34BrNO2
Molar mass508.500 g·mol
3D model (JSmol)
SMILES
  • OC(c1ccccc1)(c1ccccc1)C12CC(CCOCc3ccccc3)(CC1)CC2.
InChI
  • InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
  • Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol) and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.

It is on the World Health Organization's List of Essential Medicines. In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.

References

  1. "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
  3. ^ "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Archived from the original (PDF) on 10 July 2018. Retrieved 22 February 2016.
  4. Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
  5. "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
  6. "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Retrieved 11 July 2020.
  7. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  8. "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  9. "Umeclidinium - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
Drugs for obstructive airway diseases: asthma/COPD (R03)
Adrenergics, inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthine PDE4 inhibitors
Others/unknown
Combination products
Muscarinic acetylcholine receptor modulators
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
GSK
Subsidiaries
Current
FormerHaleon
Predecessors,
acquisitions
Products
Current
Pharma
Vaccines
Former
People
Board of
Directors
Other
Litigation
Other
Portal:


Stub icon

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

Categories: